Literature DB >> 12118019

Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.

Claus Rödel1, Gerhard G Grabenbauer, Reinhard Kühn, Thomas Papadopoulos, Jürgen Dunst, Martin Meyer, Karl M Schrott, Rolf Sauer.   

Abstract

PURPOSE: To evaluate our long-term experience with combined modality treatment and selective bladder preservation and to identify factors that may predict treatment response, risk of relapse, and survival. PATIENTS AND METHODS: Between 1982 and 2000, 415 patients with bladder cancer (high-risk T1, n = 89; T2 to T4, n = 326) were treated with radiotherapy (RT; n = 126) or radiochemotherapy (RCT; n = 289) after transurethral resection (TUR) of the tumor. Six weeks after RT/RCT, response was evaluated by restaging-TUR. In case of complete response (CR), patients were observed at regular intervals. In case of persistent or recurrent invasive tumor, salvage-cystectomy was recommended. Median follow-up was 60 months (range, 6 to 199 months).
RESULTS: CR was achieved in 72% of patients. Local control after CR without muscle-invasive relapse was maintained in 64% of patients at 10 years. Distant metastases were diagnosed in 98 patients with an actuarial rate of 35% at 10 years. Ten-year disease-specific survival was 42%, and more than 80% of survivors preserved their bladder. Early tumor stage and a complete TUR were the most important factors predicting CR and survival. RCT was more effective than RT alone in terms of CR and survival. Salvage cystectomy for local failure was associated with a 45% disease-specific survival rate at 10 years. Cystectomy because of a contracted bladder was restricted to 2% of patients.
CONCLUSION: TUR with RCT is a reasonable option for patients seeking an alternative to radical cystectomy. Ideal candidates are those with early-stage and unifocal tumors, in whom a complete TUR is accomplished.

Entities:  

Mesh:

Year:  2002        PMID: 12118019     DOI: 10.1200/JCO.2002.11.027

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  128 in total

1.  Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

Authors:  Raymond H Mak; Daniel Hunt; William U Shipley; Jason A Efstathiou; William J Tester; Michael P Hagan; Donald S Kaufman; Niall M Heney; Anthony L Zietman
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

2.  Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.

Authors:  Kevin R Kozak; Maryam Hamidi; Matthew Manning; John S Moody
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-06       Impact factor: 7.038

Review 3.  Current management of muscle-invasive bladder cancer.

Authors:  G Sancho; P Maroto; J Palou
Journal:  Clin Transl Oncol       Date:  2011-12       Impact factor: 3.405

4.  Concerning the final report "Hyperthermia: a systematic review" of the Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, March 2010.

Authors:  R Sauer; H Creeze; M Hulshof; R Issels; O Ott
Journal:  Strahlenther Onkol       Date:  2012-03       Impact factor: 3.621

5.  Urological cancer: Chemoradiation superior in muscle-invasive bladder cancer.

Authors:  Christian Weiss; Claus Rödel
Journal:  Nat Rev Clin Oncol       Date:  2012-05-29       Impact factor: 66.675

6.  [Organ-sparing chemoradiotherapy: a viable alternative to initial cystectomy for patients with muscle-invasive bladder cancer].

Authors:  C Weiss; R Sauer
Journal:  Strahlenther Onkol       Date:  2012-08       Impact factor: 3.621

Review 7.  Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder.

Authors:  Kirk A Keegan; Matthew J Resnick; Peter E Clark
Journal:  Curr Opin Oncol       Date:  2012-05       Impact factor: 3.645

Review 8.  A Practical Approach to the Management of Radiation-Induced Hemorrhagic Cystitis.

Authors:  Xavier Liem; Fred Saad; Guila Delouya
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

9.  A New Prognostic Instrument Specifically Designed for Patients Irradiated for Recurrent Carcinoma of the Bladder.

Authors:  Lisa Manig; Stefan Janssen; Steven E Schild; Dirk Rades
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

Review 10.  Bladder cancer.

Authors:  David J Gallagher; Matthew I Milowsky
Journal:  Curr Treat Options Oncol       Date:  2009-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.